Alethia Young
Stock Analyst at Cantor Fitzgerald
(2.93)
# 1,438
Out of 5,124 analysts
137
Total ratings
53.64%
Success rate
31.05%
Average return
Main Sectors:
Stocks Rated by Alethia Young
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RCUS Arcus Biosciences | Reiterates: Overweight | n/a | $23.83 | - | 5 | Jul 5, 2024 | |
| ARWR Arrowhead Pharmaceuticals | Reiterates: Overweight | n/a | $66.39 | - | 5 | Jun 20, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Neutral | $800 → $850 | $771.87 | +10.12% | 9 | Oct 16, 2023 | |
| ALXO ALX Oncology Holdings | Reiterates: Overweight | $18 | $1.13 | +1,492.92% | 6 | Sep 12, 2023 | |
| CRIS Curis | Reiterates: Overweight | $60 | $0.99 | +5,978.41% | 3 | Sep 7, 2023 | |
| ELDN Eledon Pharmaceuticals | Reiterates: Overweight | $9 | $1.51 | +496.03% | 2 | Aug 22, 2023 | |
| VSTM Verastem | Reiterates: Overweight | $34 | $7.72 | +340.41% | 2 | Jul 6, 2023 | |
| BIIB Biogen | Maintains: Neutral | $427 → $327 | $175.99 | +85.81% | 7 | Oct 15, 2021 | |
| RAPT RAPT Therapeutics | Maintains: Overweight | $408 → $568 | $33.87 | +1,577.00% | 2 | Jun 14, 2021 | |
| VRTX Vertex Pharmaceuticals | Maintains: Overweight | $285 → $281 | $453.36 | -38.02% | 5 | Jun 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $8 | $1.61 | +396.89% | 1 | Mar 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $86 → $98 | $0.98 | +9,873.54% | 3 | Feb 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $280 → $295 | $327.31 | -9.87% | 9 | Feb 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $84 → $86 | $122.74 | -29.93% | 3 | Oct 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $48 | $29.81 | +61.02% | 4 | Oct 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $7.05 | +325.53% | 1 | Oct 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $70 → $72 | $27.22 | +164.51% | 8 | Jul 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $5 | $1.87 | +167.38% | 5 | Jun 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $83 → $100 | $98.77 | +1.25% | 6 | May 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $185 → $201 | $213.24 | -5.74% | 6 | Apr 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $86 → $85 | $75.96 | +11.90% | 5 | Apr 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $32 | $15.95 | +100.63% | 1 | Mar 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $211 → $217 | $21.52 | +908.36% | 12 | Feb 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $75 → $48 | $48.48 | -0.99% | 4 | Oct 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $18.04 | - | 3 | Mar 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $151 → $154 | $397.65 | -61.27% | 5 | Mar 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $113 → $116 | $59.43 | +95.19% | 2 | Mar 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $147 → $106 | $5.95 | +1,681.51% | 8 | Jan 24, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $28 | $8.99 | +211.46% | 1 | Nov 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $85 → $82 | $184.02 | -55.44% | 2 | Sep 27, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | n/a | $487.25 | - | 1 | Mar 16, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $3.14 | - | 1 | Oct 18, 2016 |
Arcus Biosciences
Jul 5, 2024
Reiterates: Overweight
Price Target: n/a
Current: $23.83
Upside: -
Arrowhead Pharmaceuticals
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $66.39
Upside: -
Regeneron Pharmaceuticals
Oct 16, 2023
Maintains: Neutral
Price Target: $800 → $850
Current: $771.87
Upside: +10.12%
ALX Oncology Holdings
Sep 12, 2023
Reiterates: Overweight
Price Target: $18
Current: $1.13
Upside: +1,492.92%
Curis
Sep 7, 2023
Reiterates: Overweight
Price Target: $60
Current: $0.99
Upside: +5,978.41%
Eledon Pharmaceuticals
Aug 22, 2023
Reiterates: Overweight
Price Target: $9
Current: $1.51
Upside: +496.03%
Verastem
Jul 6, 2023
Reiterates: Overweight
Price Target: $34
Current: $7.72
Upside: +340.41%
Biogen
Oct 15, 2021
Maintains: Neutral
Price Target: $427 → $327
Current: $175.99
Upside: +85.81%
RAPT Therapeutics
Jun 14, 2021
Maintains: Overweight
Price Target: $408 → $568
Current: $33.87
Upside: +1,577.00%
Vertex Pharmaceuticals
Jun 11, 2021
Maintains: Overweight
Price Target: $285 → $281
Current: $453.36
Upside: -38.02%
Mar 8, 2021
Initiates: Overweight
Price Target: $8
Current: $1.61
Upside: +396.89%
Feb 25, 2021
Maintains: Overweight
Price Target: $86 → $98
Current: $0.98
Upside: +9,873.54%
Feb 3, 2021
Maintains: Overweight
Price Target: $280 → $295
Current: $327.31
Upside: -9.87%
Oct 29, 2020
Reiterates: Overweight
Price Target: $84 → $86
Current: $122.74
Upside: -29.93%
Oct 28, 2020
Maintains: Overweight
Price Target: $30 → $48
Current: $29.81
Upside: +61.02%
Oct 12, 2020
Initiates: Overweight
Price Target: $30
Current: $7.05
Upside: +325.53%
Jul 31, 2020
Maintains: Overweight
Price Target: $70 → $72
Current: $27.22
Upside: +164.51%
Jun 2, 2020
Assumes: Overweight
Price Target: $5
Current: $1.87
Upside: +167.38%
May 19, 2020
Maintains: Neutral
Price Target: $83 → $100
Current: $98.77
Upside: +1.25%
Apr 20, 2020
Reiterates: Overweight
Price Target: $185 → $201
Current: $213.24
Upside: -5.74%
Apr 8, 2020
Reiterates: Overweight
Price Target: $86 → $85
Current: $75.96
Upside: +11.90%
Mar 6, 2020
Maintains: Overweight
Price Target: $30 → $32
Current: $15.95
Upside: +100.63%
Feb 27, 2020
Reiterates: Overweight
Price Target: $211 → $217
Current: $21.52
Upside: +908.36%
Oct 3, 2019
Maintains: Neutral
Price Target: $75 → $48
Current: $48.48
Upside: -0.99%
Mar 22, 2018
Downgrades: Underperform
Price Target: n/a
Current: $18.04
Upside: -
Mar 13, 2018
Maintains: Outperform
Price Target: $151 → $154
Current: $397.65
Upside: -61.27%
Mar 2, 2018
Maintains: Outperform
Price Target: $113 → $116
Current: $59.43
Upside: +95.19%
Jan 24, 2018
Maintains: Outperform
Price Target: $147 → $106
Current: $5.95
Upside: +1,681.51%
Nov 3, 2017
Maintains: Outperform
Price Target: $24 → $28
Current: $8.99
Upside: +211.46%
Sep 27, 2017
Maintains: Neutral
Price Target: $85 → $82
Current: $184.02
Upside: -55.44%
Mar 16, 2017
Initiates: Underperform
Price Target: n/a
Current: $487.25
Upside: -
Oct 18, 2016
Initiates: Outperform
Price Target: n/a
Current: $3.14
Upside: -